WO2025096481 - TELOMERE-TARGETING PHOSPHATIDYL-THIO CONJUGATES
National phase entry:
Publication Number
WO/2025/096481
Publication Date
08.05.2025
International Application No.
PCT/US2024/053473
International Filing Date
29.10.2024
Title **
[English]
TELOMERE-TARGETING PHOSPHATIDYL-THIO CONJUGATES
[French]
CONJUGUÉS PHOSPHATIDYL-THIO CIBLANT LES TÉLOMÈRES
Applicants **
MAIA BIOTECHNOLOGY, INC.
Inventors
GRYAZNOV, Sergei
Priority Data
63/546,242
29.10.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2051 | |
| EPO | Filing, Examination, Granting | 11752 | |
| Japan | Filing, Examination, Granting | 2149 | |
| South Korea | Filing, Examination, Granting | 2034 | |
| USA | Filing, Examination, Granting | 9710 |
Total:
27,696
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are telomere-targeting phosphatidyl-thio conjugates comprising nucleoside analogs 6-thio-2'-deoxyguanosine and 6-thioguanosine, that target telomers in cancer cells as well as pharmaceutical compositions thereof, and therapeutic methods for the administration of a therapeutically effective amount of the telomere-targeting phosphatidyl-thio conjugate compounds to treat cancers, such as colorectal cancer, non-small cell lung cancer and hepatocellular cancer.[French]
L'invention concerne des conjugués phosphatidyl-thio ciblant des télomères comprenant des analogues nucléosidiques, la 6-thio-2'-désoxyguanosine et la 6-thioguanosine, qui ciblent des télomères dans des cellules cancéreuses, ainsi que des compositions pharmaceutiques associées, et des méthodes thérapeutiques pour l'administration d'une quantité thérapeutiquement efficace des composés conjugués hosphatidyl-thio ciblant les télomères pour traiter des cancers, tels que le cancer colorectal, le cancer non à petites cellules et le cancer hépatocellulaire.